Monday, 18 Mar 2019

You are here

Multiple Delays in Referral of New RA Patients

A UK study of early onset arthritis or new rheumatoid arthritis patients shows multiple sources of delayed referral to the first rheumatology consultation.

A total of 822 patients (563 female, mean age 55 years) were enrolled from 34 National Health Service trusts in England and Scotland, including networks such as the Early Rheumatoid Arthritis Network and the National Institute for Health Research Clinical Research Network. To be enrolled, adult patients had to have clinically apparent synovial swelling of one or more joints or a diagnosis of unclassified arthritis (UA) or new onset of RA (according to 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria.

Key findings included:

  • The median time between symptom onset and rheumatology consult was 27.2 weeks (IQR 14.1-66 weeks).
  • Only 20% of patients were seen within the first 3 months of symptom onset.
  • The median patient delay was 5.4 weeks (IQR 1.4-26.3 weeks).
  • The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks).
  • Patients had a mean of 4 GP visits before being referred.
  • The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Delays were prolonged in patients who purchased over-the-counter medications or used ice/heat packs took longer to seek help than those who did not.

Patients with a palindromic or an insidious symptom onset delayed for longer than those with a non-palindromic or acute onset.

The interval between first consultation with a rheumatologist and initiation of treatment was not measured in this study.

Multiple delays (patient, PCP, hospital, etc) contributed to a longer than expected time from symptom onset to rheumatologic evaluation. Patient education and delays by primary care providers will require interventions to promote more timely referrals.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Does Smoking Cessation Reduce RA Risk?

Individuals who quit smoking and maintained their nonsmoking status over a long duration of time had a decreased risk of developing seropositive rheumatoid arthritis (RA), an analysis of two large prospective cohorts found. 

Remission Unlikely in RA

Dr. Marwan Bukhari (editor of Rheumatology) has written an editorial wherein he suggests that true remission is hard to achieve. He notes that "remission as a target is a noble objective that we should all aspire to but we should not chastise our practice if we do not achieve it, as more and more evidence suggests that we should consider it the ideal but not the norm."

No Added Benefit to MRI-Guided Therapy in Rheumatoid Arthritis

A treat-to-target (T2T) strategy to manage rheumatoid arthritis hinges on clinical metrics to optimize therapy. But investigators from Denmark have shown that using magnetic resonance imaging–guided T2T failed to improve disease activity remission rates or reduce radiographic progression.

Differing Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids

Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.

Update on Pregnancy Management in RA

Two recent reports offer good news to rheumatoid arthritis (RA) women who are planning to become pregnant. 

The first studies, RA women experiencing fertility issues who turn to assisted reproductive technology (ART) shows that live births were significantly lower in women with rheumatoid arthritis receiving ART treatment compared to usual rates in women without rheumatoid arthritis.